Millions of people carry early signs of Alzheimer’s disease in their brains years before they forget a name or lose track of a conversation. A 216-week clinical trial is now testing whether the drug lecanemab can slow that invisible buildup of amyloid protein in cognitively normal adults, a direct attempt to stop the disease before memory loss even begins. The trial, known as AHEAD 3-45, represents the most ambitious test yet of whether clearing amyloid plaques at the earliest possible stage can protect cognition, and it arrives after a previous attempt with a different drug failed to show any benefit over 4.5 years.
Why treating Alzheimer’s before symptoms appear matters right now
Lecanemab, sold under the brand name LEQEMBI, already has FDA authorization for people with early symptomatic Alzheimer’s disease. Its official label covers patients who have mild cognitive impairment or mild dementia with confirmed amyloid pathology. But the AHEAD 3-45 trial asks a harder question: can the same drug work in people who have no symptoms at all?
The logic rests on a simple biological premise. Amyloid plaques accumulate for a decade or more before a person notices any cognitive trouble. By the time symptoms appear, downstream damage from tau protein tangles and neuron loss has already taken hold. If a drug can strip away amyloid while the brain is still functioning normally, the theory goes, it might prevent or delay the cascade that leads to dementia. The published design of AHEAD 3-45 lays out this rationale in detail, describing how the trial separates participants into groups based on whether they have intermediate or elevated amyloid levels on PET scans.
That distinction is central to the trial’s hypothesis. Lecanemab is a more potent amyloid-clearing agent than solanezumab, the antibody tested in the earlier A4 trial. Solanezumab targets soluble amyloid rather than the deposited plaques themselves, and the A4 trial showed it produced no cognitive or functional benefit over 4.5 years in cognitively unimpaired people with elevated amyloid, according to results published in the New England Journal of Medicine. The working expectation behind AHEAD 3-45 is that lecanemab’s stronger plaque-removal action, applied to people at even earlier stages of amyloid accumulation, will produce a measurable slowing of cognitive decline on the PACC5 composite score, the trial’s primary cognitive outcome.
What the AHEAD 3-45 trial is actually measuring
The AHEAD 3-45 study, registered as NCT04468659, is a placebo-controlled trial running for 216 weeks. It enrolls cognitively unimpaired adults who show either intermediate or elevated amyloid on brain PET imaging. The trial uses the PACC5, a five-component cognitive composite, among its outcome measures to detect subtle changes in thinking and memory that standard clinical tests would miss.
The trial’s structure reflects lessons from both the A4 failure and from trials in people who already have symptoms. The TRAILBLAZER-ALZ 2 trial of donanemab, another amyloid-clearing antibody, demonstrated that removing plaques in early symptomatic Alzheimer’s disease could slow clinical decline, according to its Phase 3 results published in JAMA. That trial also documented the safety risks of amyloid removal, particularly amyloid-related imaging abnormalities, or ARIA, which include brain swelling and small bleeds detectable on MRI. AHEAD 3-45 incorporates ARIA monitoring protocols informed by these findings, though the specific incidence rates in a cognitively normal population remain unknown because no completed prevention trial has generated that data.
The A4 trial, registered as NCT02008357, used a related but different cognitive composite called the PACC as its endpoint. Its negative result after 4.5 years of treatment raised a pointed question: did the drug fail, or did the strategy of targeting amyloid before symptoms fail? AHEAD 3-45 is designed to answer that question by using a drug with a fundamentally different mechanism of action. Lecanemab binds to amyloid protofibrils and clears deposited plaques, while solanezumab targeted only the soluble form of the protein and left plaques largely intact.
Trials in dominantly inherited Alzheimer’s disease, where people carry genetic mutations that guarantee the disease will develop, have provided additional evidence that long-duration preventive treatment is feasible. A multi-year randomized trial testing gantenerumab and solanezumab in this population, published in Nature Medicine, documented that sustained anti-amyloid treatment over years is operationally possible, even if cognitive benefits remained elusive in that setting. Those data help justify the long time horizon and intensive monitoring built into AHEAD 3-45, which similarly asks participants and clinicians to commit to years of infusions, imaging, and cognitive testing without any guarantee of individual benefit.
Who joins a prevention trial, and what they face
Participants in AHEAD 3-45 are cognitively normal at enrollment, but they have already undergone a series of steps that set them apart from the general population. They must first volunteer for screening, agree to PET imaging that can reveal elevated amyloid, and then decide whether they want to know that information and act on it. For many, learning that their brain harbors a hallmark of Alzheimer’s disease years before symptoms could be emotionally fraught, raising questions about future independence, family planning, and financial security.
Once enrolled, participants are randomized to receive either lecanemab or placebo infusions over 216 weeks. They undergo regular MRI scans to monitor for ARIA, repeated PET imaging to track amyloid levels, and detailed cognitive assessments to detect even slight changes from their personal baseline. Because they are starting from a point of normal function, any decline-whether related to drug side effects, the underlying disease, or unrelated aging-may feel particularly stark.
Ethically, prevention trials like AHEAD 3-45 must balance the potential for long-term public health benefit against the near-term burdens placed on individuals. The informed consent process has to cover not only the usual risks of an investigational drug but also the psychological impact of biomarker disclosure and the possibility that, after years of participation, the trial might still yield a null result. Investigators also have to prepare for incidental findings on MRI or PET scans that may require follow-up outside the trial itself.
What success or failure would mean
If AHEAD 3-45 shows that lecanemab meaningfully slows cognitive decline in amyloid-positive but asymptomatic adults, it would mark a turning point in how clinicians think about Alzheimer’s disease. The condition could increasingly be framed as a preventable or at least modifiable process, akin to high cholesterol and heart disease. Primary care practices might one day incorporate amyloid screening for people in their sixties or even earlier, followed by years of preventive antibody infusions for those at highest risk.
Such a shift would raise its own practical and ethical questions. Health systems would need to decide who qualifies for preventive therapy, how to pay for expensive biologic drugs over many years, and how to ensure equitable access across different communities. Regulators would have to weigh modest average benefits on composite cognitive scores against the risks of ARIA in people who currently feel perfectly well. And families would face decisions about whether to pursue biomarker testing long before any memory problems occur.
If the trial fails to show benefit, the implications will be equally significant. A negative result would not only challenge the value of lecanemab in the preclinical stage but also sharpen doubts about the centrality of amyloid in driving Alzheimer’s disease. Researchers might shift more attention and resources toward tau-targeting therapies, neuroinflammation, or entirely different biological pathways. Prevention efforts could move away from monoclonal antibodies and toward lifestyle interventions, small-molecule drugs, or combination approaches.
Either way, AHEAD 3-45 is poised to provide an unprecedented look at what happens when an amyloid-clearing therapy is deployed at the very earliest detectable phase of Alzheimer’s biology. By enrolling cognitively normal adults with biomarker evidence of disease and following them closely for more than four years, the trial will test not only a single drug but also a broader strategy: treating Alzheimer’s before it steals a single memory, in the hope that those memories will never have to be reclaimed.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
